<!DOCTYPE html>
<html lang="de">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lysosomale Speicherkrankheiten - Teil 1</title>
    <style>
        @import url('https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap');
        
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        :root {
            --primary-color: #667eea;
            --secondary-color: #764ba2;
            --accent-color: #f093fb;
            --success-color: #4facfe;
            --warning-color: #fa709a;
            --danger-color: #ff6b6b;
            --info-color: #74b9ff;
            --text-primary: #2d3748;
            --text-secondary: #4a5568;
            --text-muted: #718096;
            --bg-white: #ffffff;
            --bg-light: #f8fafc;
            --bg-lighter: #f1f5f9;
            --border-radius: 16px;
            --border-radius-lg: 24px;
            --spacing-xs: 8px;
            --spacing-sm: 16px;
            --spacing-md: 24px;
            --spacing-lg: 32px;
            --spacing-xl: 48px;
            --shadow-sm: 0 4px 6px -1px rgba(0, 0, 0, 0.1);
            --shadow-md: 0 10px 15px -3px rgba(0, 0, 0, 0.1);
            --shadow-lg: 0 20px 25px -5px rgba(0, 0, 0, 0.1);
        }
        
        body {
            font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif;
            line-height: 1.6;
            color: var(--text-primary);
            background: linear-gradient(135deg, #f8fafc 0%, #e2e8f0 100%);
            min-height: 100vh;
        }
        
        .container {
            max-width: 1400px;
            margin: 0 auto;
            padding: var(--spacing-md);
        }
        
        /* Header */
        .header {
            background: var(--bg-white);
            border-radius: var(--border-radius-lg);
            padding: var(--spacing-xl);
            margin-bottom: var(--spacing-lg);
            text-align: center;
            box-shadow: var(--shadow-md);
            border: 1px solid #e2e8f0;
        }
        
        .header h1 {
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color), var(--accent-color));
            background-size: 200% 200%;
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
            font-size: clamp(2rem, 5vw, 3.5rem);
            font-weight: 700;
            margin-bottom: var(--spacing-sm);
            animation: gradientShift 4s ease-in-out infinite;
        }
        
        @keyframes gradientShift {
            0%, 100% { background-position: 0% 50%; }
            50% { background-position: 100% 50%; }
        }
        
        .header p {
            color: var(--text-secondary);
            font-size: 1.3rem;
            font-weight: 400;
        }
        
        /* Progress bar */
        .progress-container {
            background: var(--bg-lighter);
            border-radius: 50px;
            height: 10px;
            margin-top: var(--spacing-md);
            overflow: hidden;
        }
        
        .progress-fill {
            background: linear-gradient(90deg, var(--success-color), #00f2fe);
            height: 100%;
            border-radius: 50px;
            transition: width 0.8s cubic-bezier(0.4, 0, 0.2, 1);
            position: relative;
            overflow: hidden;
        }
        
        .progress-fill::after {
            content: '';
            position: absolute;
            top: 0;
            left: 0;
            width: 100%;
            height: 100%;
            background: linear-gradient(90deg, transparent, rgba(255, 255, 255, 0.3), transparent);
            animation: progressShimmer 2s infinite;
        }
        
        @keyframes progressShimmer {
            0% { transform: translateX(-100%); }
            100% { transform: translateX(100%); }
        }
        
        /* Navigation */
        .navigation {
            background: var(--bg-white);
            border-radius: var(--border-radius);
            padding: var(--spacing-md);
            margin-bottom: var(--spacing-lg);
            display: flex;
            flex-wrap: wrap;
            gap: var(--spacing-sm);
            justify-content: center;
            box-shadow: var(--shadow-sm);
            border: 1px solid #e2e8f0;
        }
        
        .nav-btn {
            background: var(--bg-light);
            border: 2px solid #e2e8f0;
            color: var(--text-primary);
            padding: 16px 24px;
            border-radius: 50px;
            cursor: pointer;
            font-size: 14px;
            font-weight: 600;
            transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
            text-transform: uppercase;
            letter-spacing: 0.5px;
        }
        
        .nav-btn:hover {
            transform: translateY(-2px);
            box-shadow: var(--shadow-md);
            background: var(--bg-white);
            border-color: var(--primary-color);
        }
        
        .nav-btn.active {
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
            color: white;
            border-color: var(--primary-color);
            box-shadow: var(--shadow-md);
        }
        
        /* Content sections */
        .content-section {
            background: var(--bg-white);
            border-radius: var(--border-radius-lg);
            padding: var(--spacing-xl);
            margin-bottom: var(--spacing-lg);
            box-shadow: var(--shadow-md);
            border: 1px solid #e2e8f0;
            display: none;
        }
        
        .content-section.active {
            display: block;
            animation: slideInUp 0.6s cubic-bezier(0.4, 0, 0.2, 1);
        }
        
        @keyframes slideInUp {
            from {
                opacity: 0;
                transform: translateY(20px);
            }
            to {
                opacity: 1;
                transform: translateY(0);
            }
        }
        
        .section-title {
            background: linear-gradient(135deg, var(--info-color), var(--primary-color));
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
            font-size: 2.5rem;
            font-weight: 700;
            margin-bottom: var(--spacing-lg);
            position: relative;
            padding-bottom: var(--spacing-sm);
        }
        
        .section-title::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 4px;
            background: linear-gradient(135deg, var(--info-color), var(--primary-color));
            border-radius: 2px;
            animation: expandWidth 0.8s ease-out 0.3s both;
        }
        
        @keyframes expandWidth {
            from { width: 0; }
            to { width: 60px; }
        }
        
        /* Subsections */
        .subsection {
            margin-bottom: var(--spacing-lg);
            padding: var(--spacing-lg);
            background: var(--bg-light);
            border-radius: var(--border-radius);
            border: 1px solid #e2e8f0;
            transition: all 0.3s ease;
        }
        
        .subsection:hover {
            transform: translateY(-2px);
            box-shadow: var(--shadow-md);
            background: var(--bg-white);
        }
        
        .subsection h3 {
            color: var(--text-primary);
            margin-bottom: var(--spacing-md);
            font-size: 1.5rem;
            font-weight: 600;
            display: flex;
            align-items: center;
            gap: var(--spacing-xs);
        }
        
        .subsection h3::before {
            content: '';
            width: 4px;
            height: 24px;
            background: linear-gradient(135deg, var(--success-color), #00f2fe);
            border-radius: 2px;
        }
        
        .subsection p {
            color: var(--text-secondary);
            margin-bottom: 1rem;
            line-height: 1.7;
        }
        
        .subsection ul {
            color: var(--text-secondary);
            padding-left: 1.5rem;
        }
        
        .subsection li {
            margin-bottom: 0.5rem;
        }
        
        /* Tables */
        .clinical-table {
            width: 100%;
            border-collapse: separate;
            border-spacing: 0;
            margin: var(--spacing-md) 0;
            background: var(--bg-white);
            border-radius: var(--border-radius);
            overflow: hidden;
            box-shadow: var(--shadow-sm);
            border: 1px solid #e2e8f0;
        }
        
        .clinical-table th {
            background: linear-gradient(135deg, var(--info-color), var(--primary-color));
            color: white;
            padding: var(--spacing-md);
            text-align: left;
            font-weight: 600;
            font-size: 0.95rem;
            text-transform: uppercase;
            letter-spacing: 0.5px;
        }
        
        .clinical-table td {
            padding: var(--spacing-md);
            border-bottom: 1px solid #f1f5f9;
            transition: all 0.3s ease;
            color: var(--text-primary);
        }
        
        .clinical-table tbody tr:hover {
            background: #f8fafc;
        }
        
        .clinical-table tbody tr:last-child td {
            border-bottom: none;
        }
        
        /* Pathway diagrams */
        .pathway-diagram {
            background: var(--bg-white);
            border: 2px solid var(--info-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-lg);
            margin: var(--spacing-md) 0;
            box-shadow: var(--shadow-sm);
        }
        
        .pathway-diagram h4 {
            color: var(--text-primary);
            margin-bottom: var(--spacing-md);
            font-size: 1.3rem;
            font-weight: 600;
            text-align: center;
        }
        
        .pathway-diagram h5 {
            color: var(--text-primary);
            margin-bottom: var(--spacing-sm);
            font-weight: 600;
        }
        
        .pathway-diagram p {
            color: var(--text-secondary);
        }
        
        /* Enzyme boxes */
        .enzyme-box {
            display: inline-block;
            background: linear-gradient(135deg, var(--info-color), var(--primary-color));
            color: white;
            padding: 12px 20px;
            margin: 6px;
            border-radius: 12px;
            font-weight: 600;
            transition: all 0.3s ease;
            box-shadow: var(--shadow-sm);
        }
        
        .enzyme-box:hover {
            transform: translateY(-2px) scale(1.05);
            box-shadow: var(--shadow-md);
        }
        
        .enzyme-box.defect {
            background: linear-gradient(135deg, var(--danger-color), #ee5a24);
            animation: pulseGlow 2s infinite;
        }
        
        @keyframes pulseGlow {
            0%, 100% {
                transform: scale(1);
                box-shadow: var(--shadow-sm);
            }
            50% {
                transform: scale(1.02);
                box-shadow: var(--shadow-md);
            }
        }
        
        .arrow {
            display: inline-block;
            margin: 0 var(--spacing-sm);
            font-size: 1.8rem;
            color: var(--primary-color);
            transition: all 0.3s ease;
        }
        
        .arrow:hover {
            transform: scale(1.2);
            color: var(--accent-color);
        }
        
        /* Highlight boxes */
        .highlight-box {
            background: linear-gradient(135deg, #fff7ed, #fed7aa);
            border: 2px solid var(--warning-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-lg);
            margin: var(--spacing-md) 0;
            position: relative;
            box-shadow: var(--shadow-sm);
        }
        
        .highlight-box::before {
            content: '‚ö†Ô∏è';
            position: absolute;
            top: -12px;
            left: 24px;
            background: linear-gradient(135deg, var(--warning-color), #fee140);
            padding: 8px 12px;
            border-radius: 50%;
            font-size: 1.2rem;
            box-shadow: var(--shadow-sm);
        }
        
        .highlight-box h4 {
            color: #92400e;
            margin-bottom: var(--spacing-sm);
            margin-top: var(--spacing-sm);
            font-weight: 600;
        }
        
        .highlight-box p, .highlight-box ul, .highlight-box li {
            color: #92400e;
        }
        
        /* Case study boxes */
        .case-study {
            background: linear-gradient(135deg, #f0fdf4, #dcfce7);
            border: 2px solid var(--success-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-lg);
            margin: var(--spacing-md) 0;
            box-shadow: var(--shadow-sm);
        }
        
        .case-study h4 {
            color: #166534;
            margin-bottom: var(--spacing-md);
            font-size: 1.3rem;
            font-weight: 600;
            display: flex;
            align-items: center;
            gap: var(--spacing-xs);
        }
        
        .case-study p, .case-study ul, .case-study li {
            color: #166534;
        }
        
        /* Metabolite boxes */
        .metabolite-box {
            display: inline-block;
            background: linear-gradient(135deg, var(--warning-color), #fee140);
            color: white;
            padding: 10px 16px;
            margin: 4px;
            border-radius: 8px;
            font-size: 0.9rem;
            font-weight: 500;
            transition: all 0.3s ease;
            box-shadow: var(--shadow-sm);
        }
        
        .metabolite-box:hover {
            transform: translateY(-2px) scale(1.05);
            box-shadow: var(--shadow-md);
        }
        
        /* Buttons */
        .next-step {
            text-align: center;
            margin-top: var(--spacing-xl);
        }
        
        .next-btn {
            background: linear-gradient(135deg, var(--success-color), #00f2fe);
            color: white;
            border: none;
            padding: 18px 36px;
            border-radius: 50px;
            cursor: pointer;
            font-size: 16px;
            font-weight: 600;
            transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
            box-shadow: var(--shadow-md);
            text-transform: uppercase;
            letter-spacing: 1px;
        }
        
        .next-btn:hover {
            transform: translateY(-4px) scale(1.05);
            box-shadow: var(--shadow-lg);
        }
        
        /* Diagnostic flow */
        .diagnostic-flow {
            display: flex;
            flex-direction: column;
            align-items: center;
            gap: var(--spacing-md);
            margin: var(--spacing-md) 0;
        }
        
        .flow-step {
            background: var(--bg-white);
            border: 2px solid var(--info-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-md);
            max-width: 320px;
            text-align: center;
            transition: all 0.3s ease;
            color: var(--text-primary);
            box-shadow: var(--shadow-sm);
        }
        
        .flow-step:hover {
            transform: translateY(-4px) scale(1.02);
            box-shadow: var(--shadow-md);
        }
        
        .flow-arrow {
            width: 0;
            height: 0;
            border-left: 12px solid transparent;
            border-right: 12px solid transparent;
            border-top: 20px solid var(--info-color);
            animation: bounce 2s infinite;
        }
        
        @keyframes bounce {
            0%, 100% { transform: translateY(0); }
            50% { transform: translateY(-5px); }
        }
        
        .part-info {
            background: linear-gradient(135deg, #eff6ff, #dbeafe);
            border: 2px solid var(--info-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-md);
            margin-bottom: var(--spacing-lg);
            text-align: center;
            box-shadow: var(--shadow-sm);
        }
        
        .part-info h3 {
            color: var(--info-color);
            margin-bottom: var(--spacing-sm);
        }
        
        .part-info p {
            color: var(--text-secondary);
        }
        
        /* Responsive design */
        @media (max-width: 768px) {
            .container {
                padding: var(--spacing-sm);
            }
            
            .header h1 {
                font-size: 2.5rem;
            }
            
            .header p {
                font-size: 1.1rem;
            }
            
            .navigation {
                flex-direction: column;
            }
            
            .nav-btn {
                width: 100%;
                text-align: center;
            }
            
            .content-section {
                padding: var(--spacing-md);
            }
            
            .section-title {
                font-size: 2rem;
            }
            
            .subsection {
                padding: var(--spacing-md);
            }
        }
        
        @media (max-width: 480px) {
            .header {
                padding: var(--spacing-md);
            }
            
            .header h1 {
                font-size: 2rem;
            }
            
            .section-title {
                font-size: 1.8rem;
            }
        }
        
        /* Animation stagger */
        .subsection {
            animation: fadeInStagger 0.6s ease-out both;
        }
        
        @keyframes fadeInStagger {
            from {
                opacity: 0;
                transform: translateY(20px);
            }
            to {
                opacity: 1;
                transform: translateY(0);
            }
        }
        
        .subsection:nth-child(1) { animation-delay: 0.1s; }
        .subsection:nth-child(2) { animation-delay: 0.2s; }
        .subsection:nth-child(3) { animation-delay: 0.3s; }
        .subsection:nth-child(4) { animation-delay: 0.4s; }
        .subsection:nth-child(5) { animation-delay: 0.5s; }
    </style>
</head>
<body>
    <div class="container">
        <div class="header">
            <h1>üß¨ Lysosomale Speicherkrankheiten</h1>
            <p>Teil 1: Grundlagen & Mukopolysaccharidosen</p>
            <div class="progress-container">
                <div class="progress-fill" id="progressBar" style="width: 0%"></div>
            </div>
        </div>

        <div class="part-info">
            <h3>üìö Lerneinheit Teil 1</h3>
            <p>Dieser erste Teil behandelt die Grundlagen lysosomaler Speicherkrankheiten und die detaillierte Darstellung der Mukopolysaccharidosen (MPS I-VII).</p>
        </div>

        <div class="navigation">
            <button class="nav-btn active" onclick="showSection('grundlagen')">1. Grundlagen</button>
            <button class="nav-btn" onclick="showSection('biochemie')">2. Biochemie</button>
            <button class="nav-btn" onclick="showSection('mps')">3. Mukopolysaccharidosen</button>
            <button class="nav-btn" onclick="showSection('diagnostik')">4. Diagnostik</button>
        </div>

        <!-- Grundlagen -->
        <div class="content-section active" id="grundlagen">
            <h2 class="section-title">üéØ Grundlagen lysosomaler Speicherkrankheiten</h2>

            <div class="subsection">
                <h3>Definition und √úberblick</h3>
                <p>Lysosomale Speicherkrankheiten sind angeborene Stoffwechseldefekte, bei denen Enzymdefekte zu einer pathologischen Akkumulation von Substraten in den Lysosomen f√ºhren. Mit √ºber 70 verschiedenen Erkrankungen stellen sie eine der gr√∂√üten Gruppen der Speicherkrankheiten dar.</p>
                
                <div class="highlight-box">
                    <h4>Hauptkategorien lysosomaler Speicherkrankheiten</h4>
                    <ul>
                        <li><strong>Mukopolysaccharidosen (MPS)</strong> - Glykosaminoglykan-Abbau gest√∂rt</li>
                        <li><strong>Sphingolipidosen</strong> - Sphingolipid-Metabolismus betroffen</li>
                        <li><strong>Oligosaccharidosen</strong> - Oligosaccharid-Abbau defekt</li>
                        <li><strong>Mukolipidosen</strong> - Multiple Enzymdefekte</li>
                        <li><strong>Glykogenose Typ II</strong> - Lysosomale Glykogenakkumulation</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>Epidemiologie und Genetik</h3>
                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Erkrankungsgruppe</th>
                            <th>Gesamtinzidenz</th>
                            <th>H√§ufigste Formen</th>
                            <th>Vererbung</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Mukopolysaccharidosen</strong></td>
                            <td>1:25.000</td>
                            <td>MPS I, II, III, VI</td>
                            <td>Autosomal-rezessiv (au√üer MPS II)</td>
                        </tr>
                        <tr>
                            <td><strong>Sphingolipidosen</strong></td>
                            <td>1:40.000</td>
                            <td>Gaucher, Niemann-Pick</td>
                            <td>Autosomal-rezessiv</td>
                        </tr>
                        <tr>
                            <td><strong>Morbus Pompe</strong></td>
                            <td>1:40.000</td>
                            <td>Infantile/Sp√§tform</td>
                            <td>Autosomal-rezessiv</td>
                        </tr>
                        <tr>
                            <td><strong>Mukolipidosen</strong></td>
                            <td>1:100.000</td>
                            <td>ML II/III</td>
                            <td>Autosomal-rezessiv</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="subsection">
                <h3>Pathophysiologie - Grundprinzipien</h3>
                <div class="pathway-diagram">
                    <h4>Der lysosomale Abbauweg</h4>
                    <div style="display: flex; flex-direction: column; align-items: center; gap: 15px; margin: 20px 0;">
                        <div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
                            <div class="enzyme-box">Makromolek√ºl</div>
                            <span class="arrow">‚Üí</span>
                            <div class="enzyme-box">Endozytose</div>
                            <span class="arrow">‚Üí</span>
                            <div class="enzyme-box">Endosom</div>
                        </div>
                        <div style="font-size: 0.9em; color: #6b7280; text-align: center;">Aufnahme und Transport</div>
                        
                        <div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
                            <div class="enzyme-box">Endosom</div>
                            <span class="arrow">‚Üí</span>
                            <div class="enzyme-box">Lysosom-Fusion</div>
                            <span class="arrow">‚Üí</span>
                            <div class="enzyme-box">Phago-/Autolysosom</div>
                        </div>
                        <div style="font-size: 0.9em; color: #6b7280; text-align: center;">Lysosomale Fusion</div>
                        
                        <div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
                            <div class="enzyme-box">Substrat</div>
                            <span class="arrow">‚Üí</span>
                            <div class="enzyme-box defect">Lysosomales Enzym</div>
                            <span class="arrow">‚Üí</span>
                            <div class="enzyme-box">Abbauprodukte</div>
                        </div>
                        <div style="font-size: 0.9em; color: #6b7280; text-align: center;">Enzymatischer Abbau (Defekt-Stelle)</div>
                        
                        <div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
                            <div class="enzyme-box">Abbauprodukte</div>
                            <span class="arrow">‚Üí</span>
                            <div class="enzyme-box">Transport</div>
                            <span class="arrow">‚Üí</span>
                            <div class="enzyme-box">Zytoplasmaverwertung</div>
                        </div>
                        <div style="font-size: 0.9em; color: #6b7280; text-align: center;">Produkttransport und Recycling</div>
                    </div>
                </div>
            </div>

            <div class="subsection">
                <h3>Gemeinsame klinische Merkmale</h3>
                <div class="pathway-diagram">
                    <h4>Organmanifestation bei lysosomalen Speicherkrankheiten</h4>
                    <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(200px, 1fr)); gap: 20px; margin: 20px 0;">
                        <div style="text-align: center; padding: 20px; background: linear-gradient(135deg, #fef2f2, #fecaca); border-radius: 12px; border: 2px solid #ef4444;">
                            <h5 style="color: #dc2626; margin-bottom: 15px;">üß† ZNS</h5>
                            <p style="color: #dc2626;">Entwicklungsr√ºckstand</p>
                            <p style="color: #dc2626;">Neurodegeneration</p>
                            <p style="color: #dc2626;">Krampfanf√§lle</p>
                        </div>
                        
                        <div style="text-align: center; padding: 20px; background: linear-gradient(135deg, #f0fdf4, #dcfce7); border-radius: 12px; border: 2px solid #22c55e;">
                            <h5 style="color: #16a34a; margin-bottom: 15px;">ü¶¥ Skelett</h5>
                            <p style="color: #16a34a;">Dysostosis multiplex</p>
                            <p style="color: #16a34a;">Kleinwuchs</p>
                            <p style="color: #16a34a;">Gelenksteife</p>
                        </div>
                        
                        <div style="text-align: center; padding: 20px; background: linear-gradient(135deg, #fff7ed, #fed7aa); border-radius: 12px; border: 2px solid #f97316;">
                            <h5 style="color: #ea580c; margin-bottom: 15px;">üëÅÔ∏è Augen</h5>
                            <p style="color: #ea580c;">Hornhauttr√ºbung</p>
                            <p style="color: #ea580c;">Retinopathie</p>
                            <p style="color: #ea580c;">Sehst√∂rungen</p>
                        </div>
                        
                        <div style="text-align: center; padding: 20px; background: linear-gradient(135deg, #eff6ff, #dbeafe); border-radius: 12px; border: 2px solid #3b82f6;">
                            <h5 style="color: #2563eb; margin-bottom: 15px;">‚ù§Ô∏è Kardial</h5>
                            <p style="color: #2563eb;">Kardiomyopathie</p>
                            <p style="color: #2563eb;">Klappendefekte</p>
                            <p style="color: #2563eb;">Arrhythmien</p>
                        </div>
                        
                        <div style="text-align: center; padding: 20px; background: linear-gradient(135deg, #f3f4f6, #e5e7eb); border-radius: 12px; border: 2px solid #6b7280;">
                            <h5 style="color: #4b5563; margin-bottom: 15px;">ü´Å Pulmonal</h5>
                            <p style="color: #4b5563;">Atemwegsverlegung</p>
                            <p style="color: #4b5563;">Restriktive Ventilation</p>
                            <p style="color: #4b5563;">Schlafapnoe</p>
                        </div>
                        
                        <div style="text-align: center; padding: 20px; background: linear-gradient(135deg, #fdf4ff, #fae8ff); border-radius: 12px; border: 2px solid #a855f7;">
                            <h5 style="color: #7c3aed; margin-bottom: 15px;">üîä HNO</h5>
                            <p style="color: #7c3aed;">H√∂rverlust</p>
                            <p style="color: #7c3aed;">Adenotonsill√§re Hypertrophie</p>
                            <p style="color: #7c3aed;">Rhinitis</p>
                        </div>
                    </div>
                </div>
            </div>

            <div class="next-step">
                <button class="next-btn" onclick="showSection('biochemie')">Weiter zur Biochemie ‚Üí</button>
            </div>
        </div>

        <!-- Biochemie -->
        <div class="content-section" id="biochemie">
            <h2 class="section-title">‚öóÔ∏è Biochemische Grundlagen</h2>

            <div class="subsection">
                <h3>Lysosomale Enzyme und ihre Funktion</h3>
                <div class="pathway-diagram">
                    <h4>Enzymatische Ausstattung der Lysosomen</h4>
                    <div style="background: #f8fafc; padding: 20px; border-radius: 12px; margin: 20px 0; border: 1px solid #e2e8f0;">
                        <p><strong>√úber 60 verschiedene hydrolytische Enzyme:</strong></p>
                        <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(250px, 1fr)); gap: 15px; margin: 15px 0;">
                            <div>
                                <h5 style="color: #2563eb; margin-bottom: 10px;">Kohlenhydrat-abbauende Enzyme</h5>
                                <div class="metabolite-box" style="margin: 5px 0; width: 100%; text-align: center;">Œ±-Glukosidase (Pompe)</div>
                                <div class="metabolite-box" style="margin: 5px 0; width: 100%; text-align: center;">Œ≤-Galaktosidase</div>
                                <div class="metabolite-box" style="margin: 5px 0; width: 100%; text-align: center;">Œ±-Mannosidase</div>
                            </div>
                            
                            <div>
                                <h5 style="color: #dc2626; margin-bottom: 10px;">Lipid-abbauende Enzyme</h5>
                                <div class="metabolite-box" style="margin: 5px 0; width: 100%; background: linear-gradient(135deg, #dc2626, #b91c1c); text-align: center;">Œ≤-Glukozerebrosidase</div>
                                <div class="metabolite-box" style="margin: 5px 0; width: 100%; background: linear-gradient(135deg, #dc2626, #b91c1c); text-align: center;">Sphingomyelinase</div>
                                <div class="metabolite-box" style="margin: 5px 0; width: 100%; background: linear-gradient(135deg, #dc2626, #b91c1c); text-align: center;">Hexosaminidase A</div>
                            </div>
                            
                            <div>
                                <h5 style="color: #16a34a; margin-bottom: 10px;">GAG-abbauende Enzyme</h5>
                                <div class="metabolite-box" style="margin: 5px 0; width: 100%; background: linear-gradient(135deg, #16a34a, #15803d); text-align: center;">Œ±-L-Iduronidase</div>
                                <div class="metabolite-box" style="margin: 5px 0; width: 100%; background: linear-gradient(135deg, #16a34a, #15803d); text-align: center;">Iduronat-2-Sulfatase</div>
                                <div class="metabolite-box" style="margin: 5px 0; width: 100%; background: linear-gradient(135deg, #16a34a, #15803d); text-align: center;">Arylsulfatase B</div>
                            </div>
                        </div>
                    </div>
                </div>
            </div>

            <div class="subsection">
                <h3>Lysosomaler Transport und Targeting</h3>
                <div class="case-study">
                    <h4>üî¨ Mannose-6-Phosphat System</h4>
                    <p><strong>Klassischer Weg der Enzym-Sortierung:</strong></p>
                    <ul>
                        <li>Neu-synthetisierte lysosomale Enzyme erhalten M6P-Markierung</li>
                        <li>M6P-Rezeptoren im Trans-Golgi erkennen markierte Enzyme</li>
                        <li>Transport in Clathrin-beschichteten Vesikeln</li>
                        <li>Fusion mit Endosomen, dann mit Lysosomen</li>
                    </ul>
                    
                    <p><strong>Defekte im Targeting (Mukolipidosen):</strong></p>
                    <ul>
                        <li><strong>ML II (I-Cell Disease):</strong> N-Acetylglukosamin-1-Phosphotransferase-Defekt</li>
                        <li><strong>ML III:</strong> Partieller Phosphotransferase-Defekt</li>
                        <li>Folge: Multiple Enzymdefekte durch falsches Targeting</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>Speichersubstrate und ihre Herkunft</h3>
                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Substratklasse</th>
                            <th>Normale Funktion</th>
                            <th>Beispiele</th>
                            <th>Hauptquelle</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Glykosaminoglykane</strong></td>
                            <td>Strukturkomponente der EZM</td>
                            <td>Heparansulfat, Dermatansulfat</td>
                            <td>Bindegewebe, Knorpel</td>
                        </tr>
                        <tr>
                            <td><strong>Sphingolipide</strong></td>
                            <td>Membrankomponenten</td>
                            <td>GM2-Gangliosid, Glukosylceramid</td>
                            <td>Nervensystem, alle Zellen</td>
                        </tr>
                        <tr>
                            <td><strong>Glykogen</strong></td>
                            <td>Glukosespeicher</td>
                            <td>Lysosomales Glykogen</td>
                            <td>Muskel, Leber</td>
                        </tr>
                        <tr>
                            <td><strong>Oligosaccharide</strong></td>
                            <td>Glykoprotein-Seitenketten</td>
                            <td>Mannose-reiche Oligosaccharide</td>
                            <td>Glykoproteinstoffwechsel</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="subsection">
                <h3>Zellul√§re Pathophysiologie</h3>
                <div class="pathway-diagram">
                    <h4>Von der Speicherung zur Organsch√§digung</h4>
                    <div style="display: flex; flex-direction: column; align-items: center; gap: 20px; background: linear-gradient(135deg, #fef2f2, #fee2e2); padding: 20px; border-radius: 10px; margin: 20px 0; border: 2px solid #fca5a5;">
                        <div class="enzyme-box defect" style="font-size: 1.1em;">Enzymdefekt</div>
                        <span class="arrow" style="transform: rotate(90deg); color: #dc2626;">‚Üì</span>
                        
                        <div class="enzyme-box" style="background: linear-gradient(135deg, #f97316, #ea580c);">Substratakkumulation</div>
                        <span class="arrow" style="transform: rotate(90deg); color: #dc2626;">‚Üì</span>
                        
                        <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px; width: 100%;">
                            <div style="text-align: center;">
                                <div class="enzyme-box" style="background: linear-gradient(135deg, #ea580c, #dc2626);">Lysosomale Schwellung</div>
                                <p style="font-size: 0.9em; color: #dc2626; margin-top: 10px;">Zellvolumen ‚Üë</p>
                            </div>
                            <div style="text-align: center;">
                                <div class="enzyme-box" style="background: linear-gradient(135deg, #dc2626, #b91c1c);">Autophagiedefekt</div>
                                <p style="font-size: 0.9em; color: #dc2626; margin-top: 10px;">Zellerneuerung ‚Üì</p>
                            </div>
                        </div>
                        <span class="arrow" style="transform: rotate(90deg); color: #dc2626;">‚Üì</span>
                        
                        <div class="enzyme-box" style="background: linear-gradient(135deg, #b91c1c, #991b1b);">Zellfunktionsst√∂rung</div>
                        <span class="arrow" style="transform: rotate(90deg); color: #dc2626;">‚Üì</span>
                        
                        <div class="enzyme-box" style="background: linear-gradient(135deg, #991b1b, #7f1d1d);">Organsch√§digung</div>
                    </div>
                </div>
            </div>

            <div class="subsection">
                <h3>Sekund√§re zellul√§re Effekte</h3>
                <div class="highlight-box">
                    <h4>Komplex der Zellsch√§digung</h4>
                    
                    <p><strong>Autophagie-Lysosom System (ALS) St√∂rung:</strong></p>
                    <ul>
                        <li>Beeintr√§chtigte Organellen-Qualit√§tskontrolle</li>
                        <li>Akkumulation gesch√§digter Mitochondrien</li>
                        <li>Reduzierte zellul√§re Stressresistenz</li>
                    </ul>
                    
                    <p><strong>Inflammatorische Kaskade:</strong></p>
                    <ul>
                        <li>Aktivierung von Mikroglia (ZNS)</li>
                        <li>Zytokin-Release (IL-1Œ≤, TNF-Œ±)</li>
                        <li>Chronische neuroinflammatorische Prozesse</li>
                    </ul>
                    
                    <p><strong>Metabolische Sekund√§reffekte:</strong></p>
                    <ul>
                        <li>mTOR-Pathway Dysregulation</li>
                        <li>Ver√§nderte Lipid-Hom√∂ostase</li>
                        <li>Calcium-Handling St√∂rungen</li>
                    </ul>
                </div>
            </div>

            <div class="next-step">
                <button class="next-btn" onclick="showSection('mps')">Zu den Mukopolysaccharidosen ‚Üí</button>
            </div>
        </div>

        <!-- Mukopolysaccharidosen -->
        <div class="content-section" id="mps">
            <h2 class="section-title">üß¨ Mukopolysaccharidosen (MPS I-VII)</h2>

            <div class="subsection">
                <h3>√úbersicht und Klassifikation</h3>
                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>MPS Typ</th>
                            <th>Enzymdefekt</th>
                            <th>Speichersubstrat</th>
                            <th>Schweregrad</th>
                            <th>ZNS-Beteiligung</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>MPS I</strong></td>
                            <td>Œ±-L-Iduronidase</td>
                            <td>Heparansulfat, Dermatansulfat</td>
                            <td>Mild - Schwer</td>
                            <td>Schwere Formen: Ja</td>
                        </tr>
                        <tr>
                            <td><strong>MPS II</strong></td>
                            <td>Iduronat-2-Sulfatase</td>
                            <td>Heparansulfat, Dermatansulfat</td>
                            <td>Mild - Schwer</td>
                            <td>Schwere Form: Ja</td>
                        </tr>
                        <tr>
                            <td><strong>MPS III</strong></td>
                            <td>4 verschiedene Enzyme</td>
                            <td>Heparansulfat</td>
                            <td>Variabel</td>
                            <td>Schwer betroffen</td>
                        </tr>
                        <tr>
                            <td><strong>MPS IV</strong></td>
                            <td>GALNS / Œ≤-Galaktosidase</td>
                            <td>Keratansulfat, C6S</td>
                            <td>Mild - Schwer</td>
                            <td>Nein</td>
                        </tr>
                        <tr>
                            <td><strong>MPS VI</strong></td>
                            <td>Arylsulfatase B</td>
                            <td>Dermatansulfat</td>
                            <td>Mild - Schwer</td>
                            <td>Nein</td>
                        </tr>
                        <tr>
                            <td><strong>MPS VII</strong></td>
                            <td>Œ≤-Glukuronidase</td>
                            <td>Heparansulfat, Dermatansulfat, C4S</td>
                            <td>Sehr variabel</td>
                            <td>Ja</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="subsection">
                <h3>MPS I (Morbus Hurler/Scheie/Hurler-Scheie)</h3>
                <div class="case-study">
                    <h4>üî¨ Klinische Subtypen</h4>
                    
                    <p><strong>MPS IH (Hurler-Syndrom) - Schwere Form:</strong></p>
                    <ul>
                        <li><strong>Manifestation:</strong> Erste 2 Lebensjahre</li>
                        <li><strong>ZNS:</strong> Progressive geistige Behinderung</li>
                        <li><strong>Skelett:</strong> Ausgepr√§gte Dysostosis multiplex</li>
                        <li><strong>Augen:</strong> Hornhauttr√ºbung</li>
                        <li><strong>Prognose:</strong> Tod meist vor 10. Lebensjahr</li>
                    </ul>
                    
                    <p><strong>MPS IS (Scheie-Syndrom) - Milde Form:</strong></p>
                    <ul>
                        <li><strong>Manifestation:</strong> Sp√§ter Beginn</li>
                        <li><strong>ZNS:</strong> Normale Intelligenz</li>
                        <li><strong>Skelett:</strong> Milde skelettale Ver√§nderungen</li>
                        <li><strong>Besonderheiten:</strong> Karpaltunnelsyndrom h√§ufig</li>
                        <li><strong>Prognose:</strong> Normale Lebenserwartung m√∂glich</li>
                    </ul>
                    
                    <p><strong>MPS IH/S (Hurler-Scheie) - Intermedi√§r:</strong></p>
                    <ul>
                        <li>Merkmale beider Formen in mittlerer Auspr√§gung</li>
                        <li>Variable ZNS-Beteiligung</li>
                        <li>Lebensdauer oft bis ins Erwachsenenalter</li>
                    </ul>
                </div>

                <div class="highlight-box">
                    <h4>ERT und HSCT bei MPS I</h4>
                    <p><strong>Enzymersatztherapie (Laronidase):</strong></p>
                    <ul>
                        <li>Dosierung: 0,58 mg/kg w√∂chentlich i.v.</li>
                        <li>Effekte: Organomegalie ‚Üì, Lungenfunktion ‚Üë, 6-min-Gehtest ‚Üë</li>
                        <li>Limitation: Penetriert nicht ZNS oder Augen/Knochen</li>
                    </ul>
                    
                    <p><strong>H√§matopoetische Stammzelltransplantation:</strong></p>
                    <ul>
                        <li>Indikation: MPS IH vor 2. Lebensjahr</li>
                        <li>Ziel: ZNS-Progression stoppen</li>
                        <li>Outcome: Cognitive Entwicklung stabilisiert</li>
                        <li>Timing crucial: Je fr√ºher, desto besser</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>MPS II (Morbus Hunter)</h3>
                <div class="pathway-diagram">
                    <h4>Besonderheiten der X-chromosomalen Vererbung</h4>
                    <div style="background: linear-gradient(135deg, #eff6ff, #dbeafe); padding: 20px; border-radius: 10px; margin: 20px 0; border: 2px solid #3b82f6;">
                        <p><strong>Genetische Besonderheiten:</strong></p>
                        <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px; margin: 15px 0;">
                            <div>
                                <h5 style="color: #2563eb; margin-bottom: 10px;">Betroffene M√§nner</h5>
                                <ul style="color: #2563eb;">
                                    <li>Hemizygot f√ºr IDS-Gen</li>
                                    <li>Vollst√§ndige Manifestation</li>
                                    <li>Zwei Ph√§notypen: mild/schwer</li>
                                </ul>
                            </div>
                            <div>
                                <h5 style="color: #2563eb; margin-bottom: 10px;">Heterozygote Frauen</h5>
                                <ul style="color: #2563eb;">
                                    <li>X-Inaktivierung variabel</li>
                                    <li>Meist asymptomatisch</li>
                                    <li>Gelegentlich milde Symptome</li>
                                </ul>
                            </div>
                        </div>
                    </div>
                </div>

                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Merkmal</th>
                            <th>Schwere Form</th>
                            <th>Milde Form</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>ZNS-Beteiligung</strong></td>
                            <td>Ja, progredient</td>
                            <td>Nein</td>
                        </tr>
                        <tr>
                            <td><strong>Manifestationsalter</strong></td>
                            <td>2-4 Jahre</td>
                            <td>10-15 Jahre</td>
                        </tr>
                        <tr>
                            <td><strong>Hornhauttr√ºbung</strong></td>
                            <td>Nein (Differenzierung zu MPS I!)</td>
                            <td>Nein</td>
                        </tr>
                        <tr>
                            <td><strong>Lebenserwartung</strong></td>
                            <td>2.-3. Lebensjahrzehnt</td>
                            <td>Nahezu normal</td>
                        </tr>
                        <tr>
                            <td><strong>ERT verf√ºgbar</strong></td>
                            <td>Ja (Idursulfase)</td>
                            <td>Ja (Idursulfase)</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="subsection">
                <h3>MPS III (Morbus Sanfilippo A-D)</h3>
                <div class="case-study">
                    <h4>üß† Die "ZNS-MPS"</h4>
                    
                    <p><strong>Charakteristika:</strong></p>
                    <ul>
                        <li><strong>Hauptmerkmal:</strong> Schwere ZNS-Degeneration bei relativ milden somatischen Symptomen</li>
                        <li><strong>Speichersubstrat:</strong> Ausschlie√ülich Heparansulfat</li>
                        <li><strong>4 Subtypen:</strong> IIIA (h√§ufigste), IIIB, IIIC, IIID</li>
                    </ul>
                    
                    <p><strong>Klinischer Verlauf in 3 Phasen:</strong></p>
                    <ul>
                        <li><strong>Phase 1 (2-6 Jahre):</strong> Entwicklungsverz√∂gerung, Hyperaktivit√§t</li>
                        <li><strong>Phase 2 (6-10 Jahre):</strong> Verhaltensst√∂rungen, Schlafst√∂rungen, Aggressivit√§t</li>
                        <li><strong>Phase 3 (>10 Jahre):</strong> Progressive Demenz, Verlust motorischer F√§higkeiten</li>
                    </ul>
                    
                    <p><strong>Therapeutische Herausforderungen:</strong></p>
                    <ul>
                        <li>Keine etablierte ERT (ZNS-Penetration Problem)</li>
                        <li>Experimentelle Ans√§tze: Gentherapie, Substrate Reduction</li>
                        <li>Symptomatische Therapie: Verhalten, Schlaf, Epilepsie</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>MPS IV (Morbus Morquio A/B)</h3>
                <div class="highlight-box">
                    <h4>Die skelett-dominante MPS</h4>
                    
                    <p><strong>MPS IVA (GALNS-Defekt):</strong></p>
                    <ul>
                        <li><strong>H√§ufigkeit:</strong> 95% aller MPS IV F√§lle</li>
                        <li><strong>Speicher:</strong> Keratansulfat, Chondroitin-6-sulfat</li>
                        <li><strong>ERT verf√ºgbar:</strong> Elosulfase alfa</li>
                    </ul>
                    
                    <p><strong>Klinische Charakteristika:</strong></p>
                    <ul>
                        <li><strong>Intellekt:</strong> Normal (wichtigste Abgrenzung!)</li>
                        <li><strong>Skelett:</strong> Universelle Platyspondylie, Pectus carinatum</li>
                        <li><strong>Komplikationen:</strong> Atlantoaxiale Instabilit√§t (lebensbedrohlich!)</li>
                        <li><strong>Gelenke:</strong> Laxit√§t (im Gegensatz zu anderen MPS)</li>
                        <li><strong>Hornhaut:</strong> Feine punktf√∂rmige Tr√ºbungen</li>
                    </ul>
                    
                    <p><strong>Kritische Komplikation - Zervikale Myelopathie:</strong></p>
                    <ul>
                        <li>Odontoid-Hypoplasie mit atlantoaxialer Instabilit√§t</li>
                        <li>Notwendigkeit: Regelm√§√üige MRT der HWS</li>
                        <li>Bei Instabilit√§t: Neurochirurgische Fusion indiziert</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>MPS VI (Morbus Maroteaux-Lamy)</h3>
                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Organmanifest.</th>
                            <th>Milde Form</th>
                            <th>Schwere Form</th>
                            <th>Besonderheiten</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>ZNS</strong></td>
                            <td>Normal</td>
                            <td>Normal</td>
                            <td>Wichtigste Abgrenzung zu MPS I/II</td>
                        </tr>
                        <tr>
                            <td><strong>Skelett</strong></td>
                            <td>Milde Dysostosis</td>
                            <td>Schwere Dysostosis</td>
                            <td>Gibbusbildung h√§ufig</td>
                        </tr>
                        <tr>
                            <td><strong>Kardial</strong></td>
                            <td>Milde Klappenfehler</td>
                            <td>Schwere Kardiomyopathie</td>
                            <td>Haupttodesursache</td>
                        </tr>
                        <tr>
                            <td><strong>Augen</strong></td>
                            <td>Hornhauttr√ºbung</td>
                            <td>Hornhauttr√ºbung</td>
                            <td>Kornealer Hydrops m√∂glich</td>
                        </tr>
                        <tr>
                            <td><strong>Therapie</strong></td>
                            <td>ERT (Galsulfase)</td>
                            <td>ERT (Galsulfase)</td>
                            <td>Alle 2 Wochen 1 mg/kg</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="next-step">
                <button class="next-btn" onclick="showSection('diagnostik')">Zur Diagnostik ‚Üí</button>
            </div>
        </div>

        <!-- Diagnostik -->
        <div class="content-section" id="diagnostik">
            <h2 class="section-title">üî¨ Diagnostik lysosomaler Speicherkrankheiten</h2>

            <div class="subsection">
                <h3>Diagnostisches Vorgehen</h3>
                <div class="diagnostic-flow">
                    <div class="flow-step">
                        <strong>Klinischer Verdacht</strong><br>
                        Organomegalie + Entwicklungsr√ºckstand?<br>
                        Dysostosis multiplex?
                    </div>
                    <div class="flow-arrow"></div>
                    
                    <div class="flow-step">
                        <strong>Urinscreening</strong><br>
                        GAGs quantitativ/qualitativ<br>
                        Oligosaccharide
                    </div>
                    <div class="flow-arrow"></div>
                    
                    <div class="flow-step">
                        <strong>Enzymdiagnostik</strong><br>
                        Trockenblut / Leukozyten<br>
                        Kultivierte Fibroblasten
                    </div>
                    <div class="flow-arrow"></div>
                    
                    <div class="flow-step">
                        <strong>Molekulargenetik</strong><br>
                        Mutationsanalyse<br>
                        Familienscreening
                    </div>
                </div>
            </div>

            <div class="subsection">
                <h3>Urinscreening bei MPS</h3>
                <div class="pathway-diagram">
                    <h4>GAG-Ausscheidungsmuster</h4>
                    <table class="clinical-table">
                        <thead>
                            <tr>
                                <th>MPS Typ</th>
                                <th>Heparansulfat</th>
                                <th>Dermatansulfat</th>
                                <th>Keratansulfat</th>
                                <th>Chondroitin-4-sulfat</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td><strong>MPS I</strong></td>
                                <td>++</td>
                                <td>++</td>
                                <td>-</td>
                                <td>-</td>
                            </tr>
                            <tr>
                                <td><strong>MPS II</strong></td>
                                <td>++</td>
                                <td>++</td>
                                <td>-</td>
                                <td>-</td>
                            </tr>
                            <tr>
                                <td><strong>MPS III</strong></td>
                                <td>+++</td>
                                <td>-</td>
                                <td>-</td>
                                <td>-</td>
                            </tr>
                            <tr>
                                <td><strong>MPS IV</strong></td>
                                <td>-</td>
                                <td>-</td>
                                <td>+++</td>
                                <td>(+)</td>
                            </tr>
                            <tr>
                                <td><strong>MPS VI</strong></td>
                                <td>-</td>
                                <td>+++</td>
                                <td>-</td>
                                <td>-</td>
                            </tr>
                            <tr>
                                <td><strong>MPS VII</strong></td>
                                <td>++</td>
                                <td>++</td>
                                <td>-</td>
                                <td>++</td>
                            </tr>
                        </tbody>
                    </table>
                </div>
            </div>

            <div class="subsection">
                <h3>Enzymdiagnostik - Methodische Aspekte</h3>
                <div class="case-study">
                    <h4>üß™ Analytische Ans√§tze</h4>
                    
                    <p><strong>Trockenblut (DBS - Dried Blood Spot):</strong></p>
                    <ul>
                        <li><strong>Vorteile:</strong> Einfach, versendbar, Neugeborenenscreening-tauglich</li>
                        <li><strong>Verf√ºgbar f√ºr:</strong> MPS I, II, IIIB, IVA, VI, Pompe, Gaucher, Krabbe</li>
                        <li><strong>Methoden:</strong> Fluorimetrie, MS/MS</li>
                        <li><strong>Limitation:</strong> Pseudodefekte durch Inhibitoren m√∂glich</li>
                    </ul>
                    
                    <p><strong>Leukozyten-basierte Diagnostik:</strong></p>
                    <ul>
                        <li><strong>Methode:</strong> Frische oder gefrorene Leukozyten</li>
                        <li><strong>Substrat:</strong> 4-Methylumbelliferyl-Substrate</li>
                        <li><strong>Vorteil:</strong> H√∂here Spezifit√§t als DBS</li>
                        <li><strong>Nachteil:</strong> Aufwendigere Logistik</li>
                    </ul>
                    
                    <p><strong>Fibroblasten-Kultur (Goldstandard):</strong></p>
                    <ul>
                        <li><strong>Indikation:</strong> Best√§tigung grenzwertiger Befunde</li>
                        <li><strong>Weitere Tests:</strong> Komplementationsanalyse, Substratakkumulation</li>
                        <li><strong>Dauer:</strong> 2-3 Wochen f√ºr Kultivierung</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>Neugeborenenscreening</h3>
                <div class="highlight-box">
                    <h4>Lysosomale Erkrankungen im NGS</h4>
                    
                    <p><strong>Aktuell gescreente Erkrankungen (international):</strong></p>
                    <ul>
                        <li><strong>MPS I:</strong> USA, Taiwan seit >10 Jahren</li>
                        <li><strong>Morbus Pompe:</strong> USA, Taiwan, Italien</li>
                        <li><strong>Morbus Gaucher:</strong> Pilotprojekte</li>
                        <li><strong>Morbus Krabbe:</strong> New York State</li>
                    </ul>
                    
                    <p><strong>Deutschland - Aktuelle Situation:</strong></p>
                    <ul>
                        <li>Noch keine lysosomalen Erkrankungen im Regel-NGS</li>
                        <li>Pilotprojekte in Planung/Durchf√ºhrung</li>
                        <li>Diskussion √ºber MPS I und Pompe</li>
                    </ul>
                    
                    <p><strong>Herausforderungen:</strong></p>
                    <ul>
                        <li><strong>Pseudodefekte:</strong> 1-5% falsch-positive Rate</li>
                        <li><strong>Sp√§tmanifeste Formen:</strong> Therapieindikation unklar</li>
                        <li><strong>Therapieverf√ºgbarkeit:</strong> Nicht f√ºr alle Erkrankungen</li>
                        <li><strong>Kosten-Nutzen:</strong> Hohe Therapiekosten</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>Differentialdiagnostik</h3>
                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Leitsymptom</th>
                            <th>Verdachtsdiagnosen</th>
                            <th>Ausschlussdiagnostik</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Hepatosplenomegalie</strong></td>
                            <td>Gaucher, Niemann-Pick, MPS I/II/VII</td>
                            <td>Chitotriosidase, Enzymaktivit√§t</td>
                        </tr>
                        <tr>
                            <td><strong>Hornhauttr√ºbung</strong></td>
                            <td>MPS I/IV/VI/VII, Mukolipidosen</td>
                            <td>Urin-GAGs, spezifische Enzyme</td>
                        </tr>
                        <tr>
                            <td><strong>Kardiomyopathie</strong></td>
                            <td>Pompe, Danon, Fabry</td>
                            <td>Œ±-Glukosidase, Œ±-Galaktosidase</td>
                        </tr>
                        <tr>
                            <td><strong>Dysostosis multiplex</strong></td>
                            <td>Alle MPS, Mukolipidosen</td>
                            <td>Radiologie-Score, Urin-GAGs</td>
                        </tr>
                        <tr>
                            <td><strong>ZNS-Degeneration</strong></td>
                            <td>MPS I/II/III/VII, Sphingolipidosen</td>
                            <td>MRT-Pattern, Enzymdiagnostik</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="subsection">
                <h3>Bildgebende Diagnostik</h3>
                <div class="case-study">
                    <h4>üì± Radiologische Charakteristika</h4>
                    
                    <p><strong>Dysostosis multiplex - Typische Ver√§nderungen:</strong></p>
                    <ul>
                        <li><strong>Sch√§del:</strong> Makrozephalus, J-f√∂rmige Sella turcica</li>
                        <li><strong>Wirbels√§ule:</strong> Platyspondylie, Kyphoskoliose, Gibbus</li>
                        <li><strong>Thorax:</strong> Paddelrippen, Pectus carinatum</li>
                        <li><strong>Becken:</strong> Flache Azetabula, Coxa valga</li>
                        <li><strong>Extremit√§ten:</strong> Verk√ºrzung, Gelenkversteifung</li>
                    </ul>
                    
                    <p><strong>MRT-Befunde ZNS (bei ZNS-MPS):</strong></p>
                    <ul>
                        <li><strong>T2-Hyperintensit√§ten:</strong> Periventrikul√§r, Balken</li>
                        <li><strong>Atrophie:</strong> Kortex und Stammhirn progredient</li>
                        <li><strong>Speicherung:</strong> Vergr√∂√üerte Virchow-Robin-R√§ume</li>
                        <li><strong>Komplikation:</strong> Hydrozephalus bei Kleinhirnatrophie</li>
                    </ul>
                    
                    <p><strong>Karpaltunnelsyndrom (h√§ufig bei MPS IS, VI):</strong></p>
                    <ul>
                        <li>Oft eines der ersten Symptome bei Erwachsenen</li>
                        <li>Elektroneurographie zur Best√§tigung</li>
                        <li>Operative Dekompression meist erforderlich</li>
                    </ul>
                </div>
            </div>

            <div class="next-step">
                <div style="text-align: center; margin-top: 2rem; padding: 2rem; background: linear-gradient(135deg, #eff6ff, #dbeafe); border-radius: var(--border-radius); border: 2px solid var(--info-color);">
                    <h3 style="color: var(--info-color); margin-bottom: 1rem;">üéâ Teil 1 abgeschlossen!</h3>
                    <p style="color: var(--text-secondary); margin-bottom: 1.5rem;">Sie haben die Grundlagen und Mukopolysaccharidosen erfolgreich durchgearbeitet.</p>
                    <p style="color: var(--text-secondary); margin-bottom: 1.5rem;"><strong>Als n√§chstes:</strong> Teil 2 mit Sphingolipidosen, Morbus Pompe und therapeutischen Optionen</p>
                    <button class="next-btn">Weiter zu Teil 2 ‚Üí</button>
                </div>
            </div>
        </div>
    </div>

    <script>
        let currentSection = 0;
        const sections = ['grundlagen', 'biochemie', 'mps', 'diagnostik'];

        function showSection(sectionId) {
            // Hide all sections
            const allSections = document.querySelectorAll('.content-section');
            allSections.forEach(section => section.classList.remove('active'));

            // Remove active class from all nav buttons
            const allButtons = document.querySelectorAll('.nav-btn');
            allButtons.forEach(btn => btn.classList.remove('active'));

            // Show selected section
            document.getElementById(sectionId).classList.add('active');

            // Highlight active nav button
            event.target.classList.add('active');

            // Update progress bar
            currentSection = sections.indexOf(sectionId);
            const progress = ((currentSection + 1) / sections.length) * 100;
            document.getElementById('progressBar').style.width = progress + '%';

            // Scroll to top
            window.scrollTo(0, 0);
        }

        // Initialize progress bar
        document.getElementById('progressBar').style.width = '25%';
    </script>
</body>
</html>